Document Type: Original Research

Authors

1 Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Dermatopathology, Razi Hospital, Pathology Department of Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Anatomical Pathology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background & Objective: Predicting the transformation of dysplastic or congenital nevi into malignant lesions results in a significant increase in the survival of patients. Some specific gene mutations have been reported to be very helpful in this regard. Therefore, this study aimed to evaluate the prevalence of BRAF V600E mutation in dysplastic and congenital nevi.
Methods: This cross-sectional study was conducted on patients with congenital (n=30) or dysplastic (n=30) nevi. For genomic analysis, the BRAF gene mutation (V600E) was evaluated using the real-time polymerase chain reaction.
Results: The prevalence of BRAF gene (V600E) mutation was found as 1 case (3.3%) in congenital and 8 cases (26.7%) in dysplastic nevi indicating the higher prevalence of this mutation in patients with dysplastic nevi (p =0.026). Moreover, in the dysplastic nevi group, the presence of BRAF gene mutation (V600E) showed  a significant relationship with the severity of dysplasia as the mutation rate was 25% in mild cases, in comparison with 54.5% in moderate dysplasia cases (p =0.009).
Conclusion: According to the results, 3.3% of the patients with congenital nevi and 26.7% of the subjects with dysplastic nevi were positive for BRAF V600E mutation. Furthermore, the severity of dysplasia could have a positive relationship with the presence of the mutation.

Keywords

Main Subjects

  1. Ackerman LV. Malignant melanoma of the skin; clinical and pathologic analysis of 75 cases. Am J Clin Pathol. 1948;18(8):602-24. [DOI:10.1093/ajcp/18.8.602] [PMID]
  2. Pampena R, Kyrgidis A, Lallas A, Moscarella E, Argenziano G, Longo C. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol. 2017;77(5):938-45 e4. [DOI:10.1016/j.jaad.2017.06.149] [PMID]
  3. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24(5):879-97. [DOI:10.1111/j.1755-148X.2011.00880.x] [PMID] [PMCID]
  4. Lin WM, Luo S, Muzikansky A, Lobo AZ, Tanabe KK, Sober AJ, et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol. 2015;72(1):54-8. [DOI:10.1016/j.jaad.2014.09.028] [PMID]
  5. Kaddu S, Smolle J, Zenahlik P, Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res. 2002;12(3):271-8. [DOI:10.1097/00008390-200206000-00011] [PMID]
  6. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139(12):1620-4; discussion 4. [DOI:10.1001/archderm.139.12.1620] [PMID]
  7. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155(1):1-8. [DOI:10.1111/j.1365-2133.2006.07218.x] [PMID]
  8. Marghoob AA, Schoenbach SP, Kopf AW, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol. 1996;132(2):170-5. [DOI:10.1001/archderm.1996.03890260072011] [PMID]
  9. Kakavand H, Crainic O, Lum T, O'Toole SA, Kefford RF, Thompson JF, et al. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology. 2014;46(3):193-8. [DOI:10.1097/PAT.0000000000000077] [PMID]
  10. Qi RQ, He L, Zheng S, Hong Y, Ma L, Zhang S, et al. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol. 2011;131(5):1129-38. [DOI:10.1038/jid.2010.405] [PMID]
  11. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20. [DOI:10.1038/ng1054] [PMID]
  12. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15(3):249-54. [DOI:10.1016/j.cub.2005.01.031] [PMID]
  13. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-52. [DOI:10.1038/ng.356] [PMID] [PMCID]
  14. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009;69(7):3042-51. [DOI:10.1158/0008-5472.CAN-08-3563] [PMID]
  15. Marchetti MA, Kiuru MH, Busam KJ, Marghoob AA, Scope A, Dusza SW, et al. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns. Br J Dermatol. 2014;171(5):1060-5. [DOI:10.1111/bjd.13260] [PMID]
  16. Karram S, Novy M, Saroufim M, Loya A, Taraif S, Houreih MA, et al. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. Am J Dermatopathol. 2013;35(4):412-8. [DOI:10.1097/DAD.0b013e31826db181] [PMID]
  17. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015;373(20):1926-36. [DOI:10.1056/NEJMoa1502583] [PMID]
  18. Salgado CM, Basu D, Nikiforova M, Bauer BS, Johnson D, Rundell V, et al. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi. Pediatr Dev Pathol. 2015;18(1):1-9. [DOI:10.2350/14-10-1566-OA.1] [PMID]
  19. Ichii-Nakato N, Takata M, Takayanagi S, Takashima S, Lin J, Murata H, et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol. 2006;126(9):2111-8. [DOI:10.1038/sj.jid.5700366] [PMID]
  20. Wu D, Wang M, Wang X, Yin N, Song T, Li H, et al. Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population. Am J Dermatopathol. 2011;33(4):341-4. [DOI:10.1097/DAD.0b013e3181fb5bc7] [PMID]
  21. Ghasemi M, Vahedi Larijani L, Emadian O, Yazdani J, Sajadianfar A, Abediankenari S. Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients. Iran J Pathol. 2019;14(1):8-16. [DOI:10.30699/ijp.14.1.8] [PMID] [PMCID]
  22. Dessars B, De Raeve LE, Morandini R, Lefort A, El Housni H, Ghanem GE, et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol. 2009;129(1):139-47. [DOI:10.1038/jid.2008.203] [PMID]
  23. Tan JM, Lin LL, Lambie D, Flewell-Smith R, Jagirdar K, Schaider H, et al. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. JAMA Dermatol. 2015;151(4):417-21. [DOI:10.1001/jamadermatol.2014.3775] [PMID]
  24. Saroufim M, Novy M, Taraif S, Habib RH, Loya A, Rauscher B, et al. BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter? J Eur Acad Dermatol Venereol. 2014;28(5):615-25. [DOI:10.1111/jdv.12148] [PMID]
  25. Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol. 2007;29(6):534-7. [DOI:10.1097/DAD.0b013e3181584950] [PMID]
  26. Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res. 2005;15(5):401-7. [DOI:10.1097/00008390-200510000-00008] [PMID]